Dr Reddys Laboratories (RDY) Receivables (2012 - 2026)

Dr Reddys Laboratories' Receivables history runs 15 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• In Q1 2026, Receivables rose 6.04% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 6.04% YoY), while the FY2026 annual figure was $1.1 billion, up 1.98% from the prior year.
• Receivables was $1.1 billion for Q1 2026 at Dr Reddys Laboratories, up from -$88.2 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $1.1 billion in Q1 2026 to a low of -$127.3 million in Q3 2022.
• Historically, Receivables has averaged $460.8 million across 5 years, with a median of $457.2 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Receivables soared 125.55% in 2023, then slumped 496.12% in 2025.
• A 5-year view of Receivables shows it stood at -$127.3 million in 2022, then jumped by 125.55% to $32.5 million in 2023, then tumbled by 253.5% to -$49.9 million in 2024, then slumped by 76.55% to -$88.2 million in 2025, then soared by 1356.16% to $1.1 billion in 2026.
• The last three Receivables figures came in at $1.1 billion (Q1 2026), -$88.2 million (Q3 2025), and -$56.2 million (Q2 2025), per Business Quant data.